3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
17
Glioblastoma
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Brenner Tumor
6
Melanoma
5
Uterine Cervical Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Gliosarcoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oligodendroglioma
3
Neoplasm Metastasis
3
Lymphoma, Large B-Cell, Diffuse
3
Colonic Neoplasms
3
Uveal Melanoma
2
Spinal Cord Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Medulloblastoma
2
Glioma
2
Endometrial Adenocarcinoma
2
Carcinoma
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
Disulfides
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts